<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2670">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327570</url>
  </required_header>
  <id_info>
    <org_study_id>COntAGIouS</org_study_id>
    <nct_id>NCT04327570</nct_id>
  </id_info>
  <brief_title>In-depth Immunological Investigation of COVID-19.</brief_title>
  <acronym>COntAGIouS</acronym>
  <official_title>In-depth Characterisation of the Dynamic Host Immune Response to Coronavirus SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COntAGIouS trial (COvid-19 Advanced Genetic and Immunologic Sampling; an in-depth
      characterization of the dynamic host immune response to coronavirus SARS-CoV-2) proposes a
      transdisciplinary approach to identify host factors resulting in hyper-susceptibility to
      SARS-CoV-2 infection, which is urgently needed for directed medical interventions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall aim of this prospective study is to provide an in-depth characterization of
      clinical and immunological features of patients hospitalized in UZ Leuven because of
      SARS-CoV-2 infection. For this purpose, clinical data and blood, nasopharyngeal/rectal swab,
      and if safe, bronchoalveolar lavage (BAL) fluid and lung tissue samples will be collected
      from PCR- or CT-confirmed COVID-19 patients, with varying degrees of disease severity.
      Assessed characteristics will be compared between severe and non-severe COVID-19 patients,
      and between COVID-19 positive and negative ('control') patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Clinical Features</measure>
    <time_frame>6 months</time_frame>
    <description>Description of clinical, laboratory and radiological features of illness and complications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune host response at systemic level</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of dynamic host immune response at systemic level (immune signalling molecules in plasma, peripheral blood mononuclear cell isolation for advanced immunophenotyping and transcriptomics). Real-time analysis using CyTOF will be performed as screening, in combination with in-depth immunophenotyping.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune host response at local level</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of dynamic host immune response at systemic level (immune signalling molecules in plasma, peripheral blood mononuclear cell isolation for advanced immunophenotyping and transcriptomics).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Host genetic variation</measure>
    <time_frame>6 months</time_frame>
    <description>Identification of host genetic variants that are associated with severity of disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison severe and non-severe COVID-19 hospitalised patients</measure>
    <time_frame>6 months</time_frame>
    <description>Differences in baseline factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison severe and non-severe COVID-19 hospitalised patients</measure>
    <time_frame>6 months</time_frame>
    <description>Differences in immune characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of findings with outcome</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation of findings with outcome, aiming to identify early biomarkers of severe disease and putative targets for immunomodulatory therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of immune profiling - microbiome</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation of immune profiling with microbiome analysis of patients</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronavirus Infections</condition>
  <arm_group>
    <arm_group_label>ICU-hospitalised COVID-19 patients</arm_group_label>
    <description>COVID-19 positive patients hospitalised in intensive care ('severe disease').</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ward-hospitalised COVID-19 patients</arm_group_label>
    <description>COVID-19 positive patients requiring hospitalisation,not on intensive care department ('non-severe').</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient sampling</intervention_name>
    <description>Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable</description>
    <arm_group_label>ICU-hospitalised COVID-19 patients</arm_group_label>
    <arm_group_label>ward-hospitalised COVID-19 patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, plasma, PBMC, BAL, lung tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All non-immunosuppressed* consecutive patients (&gt;18 years old) that are admitted to UZ
        Leuven from March 2020 until September 2020 with PCR-confirmed and/or CT-confirmed
        SARS-CoV-2 disease are eligible for inclusion.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;/= 18 years old AND

          -  Hospitalised with PCR-confirmed and/or CT-confirmed SARS-CoV-2 disease

        Exclusion Criteria:

          -  Age &lt; 18 years old

          -  No informed consent

          -  Patients on cyclosporine/tacrolimus/sirolimus/everolimus therapy*
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joost Wauters, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joost Wauters, MD PhD</last_name>
    <phone>003216344275</phone>
    <email>joost.wauters@uzleuven.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joost Wauters, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

